Introducing: Polaryx® Therapeutics
Polaryx® Therapeutics, Inc is a biotech company devoted to the development of therapeutic interventions for Neuronal Ceroid Lipofuscinosis (NCL), a group of rare genetic lysosomal storage disorders in children.
NCL is also known as Batten disease. Among the subtypes of NCL, we are focusing on the development of patient-friendly oral medications for Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL or CLN2).
Children with CLN2 have progressive deterioration of their mental and motor functions, visual failure, and seizures leading to premature death. The disease has no cure, and thus has a high unmet medical need.
We are collaborating with leading
academic medical institutions,
including Rush University
Medical Center in Chicago.
Great minds, united for one cause
We are collaborating with leading academic medical institutions, including Rush University Medical Center in Chicago.
In addition, with the concerted cooperation and expertise of our management and development teams, including highly qualified CROs and world-renowned scientists, we are dedicated to the development of a safe and efficacious treatment for Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL or CLN2).
Our team has over 100 years of combined experience in pioneering biotechnology and pharmaceutical industries and in top-notch academic institutions.
These exceptional qualifications of our team allow us to develop therapeutic interventions with disease modifying potential to improve the patient's quality of life.
Our creativity, knowledge, experience, and high level of business acumen will allow Polaryx® Therapeutics Inc to find the right solution to save the lives and improve the quality of life of patients suffering from this devastating genetic disorder.